Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Diabetes & Metabolic Disorders
Published in: Journal of Diabetes & Metabolic Disorders 1/2023

22-12-2022 | Stroke | Research article

Peroxisome proliferator-activated receptor γ Pro12 ala polymorphism and risk of cerebral stroke in type 2 diabetes mellitus egyptian patients

Authors: Reham M. El-Farahaty, Osama Fouda, Amany EL-Deasty, Abdel-Hady El-Gilany, Narmin Saied

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2023

Login to get access

Abstract

Objectives

This study aimed to analyze the association of the peroxisome proliferator activated receptor gamma (PPARγ) P12A (rs1801282) polymorphism with development of cerebral stroke in patients with type 2 diabetes mellitus.

Methods

We included 224 patients with diabetes, they were categorized into116 patients with ischemic stroke (IS) and 108 without IS, in addition to 148 healthy controls in this study. respectively. Anthropometric parameters and laboratory tests were measured. The polymorphism was detected by a PCR-RFLP method.

Results

A12 allele and A12 containing genotypes show significant higher percentage in patients with diabetes and IS in comparison to diabetes patients without IS (9.1 vs. 4.2%,16.4 vs7.4%; P = 0.044,0.044) with OR of 2.29 and 2. 449 respectively (95% CI: 1.024–5.115, 1.024–5.856) but does not withstand Bonferroni correction.

Conclusion

A12 containing genotypes and A12 allele are not associated with IR, diabetes and risk of IS development, however, significant higher BMI were observed in A12 allele carriers in the studied patients with diabetes as well as those with IS.
Literature
1.
Quinn L. Type 2 diabetes: epidemiology, pathophysiology, and diagnosis. NursClin North Am. 2001;36(2):175–92.CrossRef
2.
3.
Ergul A, Kelly-Cobbs A, Abdalla M, Fagan SC. Cerebrovascular complications of diabetes: Focus on Stroke. EndocrMetab Immune Disord Drug Targets. 2012;12(2):148–58.CrossRef
4.
Arnett DK, Baird AE, Barkley RA, Basson CT, Boerwinkle E, Ganesh SK, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2007;115(22):2878–901.CrossRefPubMed
5.
Stumvoll M, Ha¨ring H. The peroxisome proliferator–activated receptor γ2 Pro12Ala polymorphism. Diabetes. 2002;51(8):2341–7.CrossRefPubMed
6.
Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006;26:28–40.CrossRefPubMed
7.
Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun. 1997;241:270–4.CrossRefPubMed
8.
Kim SY, Kim HI, Park SK, Im SS, Li T, Cheon HG, et al. Liver glucokinase can be activated by peroxisome proliferatoractivated receptor-gamma. Diabetes. 2004;53(Suppl 1):66–70.CrossRef
9.
Gonzalez JPM, Borrella CC, Mayoral R, Gudino LC, Hoghtower CM, Sarmiento RG. PPAR gamma pro12Ala polymorphism and type 2 diabetes: a study in a spanishcohort. J Genet Stud. 2014;2:1.CrossRef
10.
Jin J, Ding G, Bao H, Chen Y, Han Y, Zhao F,et al. Correlation between PPAR gene polymorphisms and primary nephrotic syndrome in children. PPAR Res. 2013;ID 927915:1–8.CrossRef
11.
Radha V, Vimaleswaran K, Narayan SH, Abate N, Chandalia M, Satija P, et al. Role of genetic polymorphism peroxisome proliferator–activated Receptor- γ 2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and caucasian subjects. Diabetes Care. 2006;29:1046–51.CrossRefPubMed
12.
Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26:76–80.CrossRefPubMed
13.
Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. BiochemBiophys Res Commun. 2000;271:212–6.CrossRef
14.
Scacchi R, Pinto A, Rickards O, Pacella A, De Stefano GF, Cannella C, et al. An analysis of peroxisome proliferator-activated receptor gamma (PPAR-gamma 2) Pro12Ala polymorphism distribution and prevalence of type 2 diabetes mellitus (T2DM) in world populations in relation to dietary habits. NutrMetabCardiovasc Dis. 2007;17:632–41.
15.
Sarhangi N, Sharif F, Hashemian L, Doabsari MH, Heshmatzad K, Rahbaran M, et al. PPARG (Pro12Ala) genetic variant and risk ofT2DM: a systematic review and metaanalysis. Sci Rep. 2020;10:12764.CrossRefPubMedPubMedCentral
16.
Wan J, Xiong S, Chao S, Xiao J, Ma Y, Wang J, Roy S. PPARg gene C161T substitution alters lipid profile in chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc Diabetol. 2010;9:13.CrossRefPubMedPubMedCentral
17.
Beyer AM, de Lange WJ, Halabi CM, Modrick ML, Keen HL, Faraci FM, et al. Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ Res. 2008;103:654–61.CrossRefPubMedPubMedCentral
18.
Hsieh F-I, Wei-Cheng LO, Lin H-J, Hsieh Y-C, Lien L-W, Bai C-H, et al. Significant synergistic effect of peroxisome proliferator–activated receptor γ C-2821T and diabetes on the risk of ischemic stroke. Diabetes Care. 2009;32:2033–5.CrossRefPubMedPubMedCentral
19.
Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, et al. Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J ClinEndocrinolMetab. 2004;89:4238–42.CrossRef
20.
Al-Shali KZA, House AA, Anthony JG, Hanley AJG, Khan HMR, Harris SB, et al. Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ Associated with Carotid atherosclerosis. Stroke. 2004;35:2036–40.CrossRefPubMed
21.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl. 1):81–90.CrossRef
22.
National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the national cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002. 17;106(25):3143–421.
23.
Tangvarasittichai S, Poonsub P, Tangvarasittichai O. Association of serum lipoprotein ratios with insulin resistance in type 2 diabetes mellitus. Indian J Med Res. 2010;131:641–8.PubMed
24.
25.
Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults,1999–2000. JAMA. 2002;288:1723–7.CrossRefPubMed
26.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. ClinChem. 1972;18(6):499–502.
27.
Hermans MP, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: discriminant ratio and unbiased equivalence. Cardiovasc Diabetol. 2011;10:20.CrossRefPubMedPubMedCentral
28.
Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J,et al. The Pro12 ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes. 2001;50:891–4.CrossRefPubMed
29.
No Association between Pro12Ala polymorphism in Peroxisome Proliferator Activated Receptor Gamma 2 gene. and type 2 diabetes in a Cameroonian population E.P. Mofo Mato a,c a,c, E. Sobngwi b,c,d, O. Donfack Sontsa a,c, E.N. Ndonwi a,c, M. Guewo Fokeng a,c, P. Fosso Pokam a,c, E. Djahmeni d, B. Atogho Tiedeu a,c, M.S. Evehe a,c, R. DjokamDadjeu a,c, F. Aminkeng e, W.F. Mbacham a,f, J.C. Mban.DIABETES RESEARCH A N D CLINICAL PRACTICE 103S (2 014) 103(1):S37-S38.
30.
31.
Iwata E, Yamamoto I, Motomura T, Tsubakimori S, Nohnen S, Ohmoto M, et al. The association of Pro12Ala polymorphism in PPARgamma2 with lower carotid artery IMT in japanese. Diabetes ResClinPract. 2003;62:55–9.
32.
Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, et al. Alanine for proline substitution in the peroxisome proliferatoractivated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. ArteriosclerThrombVasc Biol. 2003;23:859–63.CrossRef
33.
Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284–7.CrossRefPubMed
34.
Zafarmand MH, van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML. Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction,coronary heart disease and ischemic stroke: a case cohort study and meta-analyses. Vasc Health Risk Manag. 2008;4:427–36.CrossRefPubMedPubMedCentral
35.
Hsieh FI, Lo WC, Lin HJ, Hsieh YC, Lien LM, Bai CH. e al. Significant synergistic effect of peroxisome proliferator–activated receptor gamma c-2821t and diabetes on the risk of ischemic stroke. Diabetes Care. 2009;32:2033–5.CrossRefPubMedPubMedCentral
36.
Lee BC, Lee HJ, Chung JH. Peroxisome proliferator- activated receptor- γ 2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes. Neurosci Lett. 2006;410:141–5.CrossRefPubMed
37.
38.
Tai ES, Corella D, Deurenberg-Yap M, Adiconis X, Chew SK, Tan CE, et al Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 2004;45:674–85.
39.
Mansoori A, Amini M, Kolahdooz F, Seyedrezazadeh E. Obesity and Pro12Ala Polymorphism of Peroxisome Proliferator-Activated Receptor-Gamma Gene in Healthy Adults: A Systematic Review and Meta-Analysis. Ann Nutr Metab 2015;67:104–118. https://​doi.​org/​10.​1159/​000439285.
40.
Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, et al Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 1999; 48: 1466–1468.
41.
Bouhaha R, Meyre D, Kamoun HA, Ennafaa H, Vaillant E, Sassi R, et al Effect of ENPP1/PC-1-K121Q and PPARgamma-Pro12Ala polymorphisms on the genetic susceptibility to T2D in the Tunisian population. Diabetes Res ClinPract 2008; 81:278–283.
42.
Kolehmainen M, Uusitupa MI, Alhava E, Laakso M, Vidal H. Effect of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects. J Clin Endocrinol Metab 2003; 88:1717–1722.
43.
Hegele Cao RA, Harris H, Zinman SB, Hanley B, Anderson AJ CM. Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 2000; 85:2014–9.
44.
Meirhaeghe Amouyel A, P. Impact of genetic variation of PPAR in humans.Mol Genet Metab. 2004;83:93–102.
45.
Oh EY, Min, Chung KM, Min JH, Lee YK, Kim MS KW,et al. Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab 2000;85:1801–4.
46.
Soriguer F1, Morcillo Cardona S, Rojo-Martínez F, G, de la Cruz Almaráz M, Ruiz de Adana Mde L, et al. Pro12Ala Polymorphism of the PPARG2 Gene Is Associated with Type 2 Diabetes Mellitus and Peripheral Insulin Sensitivity in a Population with a High Intake of Oleic Acid. J Nutr 2006; 136: 2325–2330.
47.
Okita k, Iwahashi H, Kozawa J, Okauchi Y, Funahashi T, Imagawa A, et al. Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy. Endocr J 2013; 60 (3): 283–290.
48.
McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005;1(3):399–404. 96.CrossRef
49.
Zietz B, Barth N, Spiegel D, Schmitz G, Scholmerich J, Schaffler A. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetes patients. Exp Clin Endocrinol Diabetes. 2002;110:60–6.CrossRefPubMed
50.
Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, et al. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disor. 2000;24:195–9.CrossRef
Metadata
Title
Peroxisome proliferator-activated receptor γ Pro12 ala polymorphism and risk of cerebral stroke in type 2 diabetes mellitus egyptian patients
Authors
Reham M. El-Farahaty
Osama Fouda
Amany EL-Deasty
Abdel-Hady El-Gilany
Narmin Saied
Publication date
22-12-2022
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2023
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-022-01159-0

Other articles of this Issue 1/2023

Journal of Diabetes & Metabolic Disorders 1/2023 Go to the issue

Research article

KADAM topical warm oxygen therapy device for diabetic foot ulcer-a novel approach

Research Article

Inactive matrix Gla protein in relation to diabetic retinopathy in type 2 diabetes

Study Protocol

Effect of bread fortification with pomegranate peel powder on glycemic indicators, antioxidant status, inflammation and mood in patients with type 2 diabetes: study protocol for a randomized, triple-blind, and placebo-controlled trial

Review Article

Nanotheranostics: application of nanosensors in diabetes management

Research article

Health literacy and self-efficacy of the elderly with diabetes

Research Article

Effect of novel Matrix Rhythm Therapy (MaRhyThe®) on neuropathic pain and maximum plantar pressure distribution among type 2 diabetes mellitus patients with peripheral neuropathy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits